You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 8,450,344


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,450,344
Title:Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Abstract: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
Inventor(s): deLong; Mitchell A. (Raleigh, NC), Sturdivant; Jill Marie (Chapel Hill, NC), Royalty; Susan M. (Cary, NC)
Assignee: Aerie Pharmaceuticals, Inc. (Research Triangle Park, NC)
Application Number:12/180,259
Patent Claims: 1. A compound of formula (I): ##STR00062## or any optical isomer, diastereomer, enantiomer, tautomer, or physiologically acceptable salt thereof; wherein R.sub.1 and R.sub.2 are, independently, hydrogen, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.1-C.sub.4 carbonyl, C.sub.1-C.sub.4 carbonylamino, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 sulfonyl, C.sub.1-C.sub.4 sulfonylamino, C.sub.1-C.sub.4 thioalkyl or C.sub.1-C.sub.4 carboxyl; or R.sub.1 and R.sub.2 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms, or R.sub.1 and R.sub.3 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms; wherein one of R.sub.3 and R.sub.4 is an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, or C.sub.2-C.sub.8 alkynyl, and the other of R.sub.3 and R.sub.4 is hydrogen or C.sub.1-C.sub.4 alkyl, the stereocenters being either `R` or `S` in configuration independently; and wherein X.sub.1 and X.sub.2 are, independently, hydrogen, hydroxyl, halogen, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 alkynyl, amino, nitro, cyano, C.sub.1-C.sub.4 carbonyl, C.sub.1-C.sub.4 carbonylamino, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 sulfonyl, C.sub.1-C.sub.4 sulfonylamino, C.sub.1-C.sub.4 thioalkyl or C.sub.1-C.sub.4 carboxyl.

2. The compound according to claim 1, wherein one of R.sub.3 and R.sub.4 is C.sub.1-C.sub.8 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.

3. The compound according to claim 2, wherein R.sub.1 and R.sub.2 are, independently, hydrogen or methyl.

4. The compound according to claim 1, wherein X.sub.1 and X.sub.2 are, independently, hydrogen, hydroxy, chloro or fluoro.

5. The compound according to claim 1, wherein one of R.sub.3 and R.sub.4 is C.sub.1-C.sub.8 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein R.sub.1 and R.sub.2 are, independently, hydrogen or methyl; and wherein X.sub.1 and X.sub.2 are, independently, hydrogen, hydroxyl, chloro or fluoro.

6. The compound according to claim 5, wherein the other of R.sub.3 and R.sub.4 is hydrogen.

7. The compound according to claim 1, wherein one of R.sub.3 and R.sub.4 is aryl or heteroaryl.

8. The compound according to claim 7, wherein one of R.sub.3 and R.sub.4 is thienyl.

9. The compound according to claim 7, wherein one of R.sub.3 and R.sub.4 is monosubstituted phenyl or monosubstituted thienyl.

10. The compound according to claim 9, wherein the substituent is fluoro, chloro or cyano.

11. The compound according to claim 7, wherein one of R.sub.3 and R.sub.4 is unsubstituted phenyl or unsubstituted thienyl.

12. The compound according to claim 1, wherein X.sub.1 is hydroxy and X.sub.2 is hydrogen.

13. The compound according to claim 1, wherein a hydroxy is at the 1-position.

14. The compound according to claim 1, wherein a hydrogen is at the 1-position.

15. The compound according to claim 1 having a formula of: TABLE-US-00014 ##STR00063## X R.sub.3 R.sub.2 R.sub.1 H (S)--C.sub.6H.sub.5 H H H (R)--C.sub.6H.sub.5 H H OH (S)--C.sub.6H.sub.5 H H OH (R)--C.sub.6H.sub.5 H H OH (S)--C.sub.6H.sub.5 Me Me H (.+-.)-o-chloro-C.sub.6H.sub.4 H H OH (.+-.)-o-chloro-C.sub.6H.sub.4 H H H (.+-.)-p-fluoro-C.sub.6H.sub.4 H H OH (.+-.)-p-fluoro-C.sub.6H.sub.4 H H H (S)-3-thienyl H H OH (S)-3-thienyl H H H (S)-3-thienyl Me Me OH (S)-3-thienyl Me Me H (S)-2-thienyl Me Me

or the formula: TABLE-US-00015 ##STR00064## X R.sub.4 R.sub.2 R.sub.1 OH (.+-.)-3-thienyl Me Me H C.sub.6H.sub.5 H H H C.sub.6H.sub.5 Me Me OH C.sub.6H.sub.5 H H

or the formula: TABLE-US-00016 ##STR00065## X R.sub.1 R.sub.2 R.sub.3 H (S)--C.sub.6H.sub.5 Me Me H (R)-3-thienyl H H OH (R)-3-thienyl H H H (S)-2-thienyl H H OH (S)-2-thienyl H H OH (S)-2-thienyl Me Me H (R)--CH.sub.2-3-thienyl H H H (S)--CH.sub.2-2-thienyl H H H (S)-2-furyl H H H (S)-3-pyridyl H H H (S)-2-methoxy-5- H H pyridyl ##STR00066## ##STR00067## ##STR00068## ##STR00069##

or the formula: TABLE-US-00017 ##STR00070## X R.sub.1 R.sub.2 R.sub.3 H (.+-.)-3-thienyl H H H (.+-.)-3-thienyl Me Me H C.sub.6H.sub.5 Me H H 4-fluoro-C.sub.6H.sub.4 H H ##STR00071## ##STR00072## ##STR00073##

16. The compound according to claim 1, wherein R.sub.1 and R.sub.2 are, independently, hydrogen or methyl; R.sub.3 is hydrogen, R.sub.4 is phenyl; X.sub.1 and X.sub.2 are hydrogen.

17. A compound of formula (II): ##STR00074## or any optical isomer, diastereomer, enantiomer, tautomer, or physiologically acceptable salt thereof; wherein R.sub.1 and R.sub.2 are, independently, hydrogen, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.1-C.sub.4 carbonyl, C.sub.1-C.sub.4 carbonylamino, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 sulfonyl, C.sub.1-C.sub.4 sulfonylamino, C.sub.1-C.sub.4 thioalkyl or C.sub.1-C.sub.4 carboxyl; or R.sub.1 and R.sub.2 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms, or R.sub.1 and R.sub.3 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms; wherein one of R.sub.3, R.sub.4 and R.sub.5 is an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, or C.sub.2-C.sub.8 alkynyl, and the other two of R.sub.3, R.sub.4 and R.sub.5 are, independently, hydrogen or C.sub.1-C.sub.4 alkyl, the stereocenters being either `R` or `S` in configuration independently; and wherein, X.sub.1 and X.sub.2 are, independently, hydrogen, hydroxyl, halogen, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 alkynyl, amino, nitro, cyano, C.sub.1-C.sub.4 carbonyl, C.sub.1-C.sub.4 carbonylamino, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 sulfonyl, C.sub.1-C.sub.4 sulfonylamino, C.sub.1-C.sub.4 thioalkyl or C.sub.1-C.sub.4 carboxyl.

18. The compound according to claim 17, wherein one of R.sub.3, R.sub.4 and R.sub.5 is C.sub.r C.sub.5 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.

19. The compound according to claim 18, wherein R.sub.1 and R.sub.2 are, independently, hydrogen or methyl.

20. The compound according to claim 17, wherein X.sub.1 and X.sub.2 are, independently, hydrogen, hydroxy, chloro or fluoro.

21. The compound according to claim 17, wherein one of R.sub.3, R.sub.4 and R.sub.5 is C.sub.1-C.sub.8 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein R.sub.1 and R.sub.2 are, independently, hydrogen or methyl; and wherein X.sub.1 and X.sub.2 are, independently, hydrogen, hydroxyl, chloro or fluoro.

22. The compound according to claim 21, wherein the other of R.sub.3, R.sub.4 and R.sub.5 are hydrogen.

23. The compound according to claim 17, wherein one of R.sub.3, R.sub.4 and R.sub.5 is aryl or heteroaryl.

24. The compound according to claim 23, wherein one of R.sub.3, R.sub.4 and R.sub.5 is thienyl.

25. The compound according to claim 23, wherein one of R.sub.3, R.sub.4 and R.sub.5 is monosubstituted phenyl or monosubstituted thienyl.

26. The compound according to claim 25, wherein the substituent is fluoro, chloro or cyano.

27. The compound according to claim 23, wherein one of R.sub.3, R.sub.4 and R.sub.5 is unsubstituted phenyl or unsubstituted thienyl.

28. The compound according to claim 17, wherein X.sub.1 is hydroxy and X.sub.2 is hydrogen.

29. The compound according to claim 17, wherein a hydroxy is at the 1-position.

30. The compound according to claim 17, wherein a hydrogen is at the 1-position.

31. The compound according to claim 17, wherein R.sub.1 and R.sub.2 are, independently, hydrogen or methyl; R.sub.3 and R.sub.4 are hydrogen, R.sub.5 is phenyl; X.sub.1 and X.sub.2 are hydrogen.

32. A composition comprising a compound according to claim 1 and a carrier.

33. The composition of claim 32, wherein the carrier is saline buffered to a pH of about 5.5 to about 6.5.

34. A composition comprising a compound according to claim 17 and a carrier.

35. The composition of claim 34, wherein the carrier is saline buffered to a pH of about 5.5 to about 6.5.

36. A method of treating a disease in a subject comprising: administering to a subject an effective amount of a compound according to claim 1; wherein the disease comprises eye disease.

37. The method of claim 36, wherein the eye disease comprises glaucoma or a neurodegenerative eye disease.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.